For research use only.
Catalog No.S1747 Synonyms: BAY E 9736
CAS No. 66085-59-4
Nimodipine (BAY E 9736) is a dihydropyridine calcium channel blocker and an autophagy inhibitor, used in the treatment of high blood pressure.
1 Customer Review
Assessment of the role of Ca2+ channels during RSV replication. HEp-2 cells were infected with RSV strain long at an MOI of 0.1, and treated with calcium channel blockers nifedipine, nimodipine, and tetrandrine (A), at indicated concentrations. Supernatants were collected at 48 h postinfection and viral titers were determined by immunoplaque assay. Grey bars represent cytotoxicity of the compounds. The data presented were obtained from two independent experiments. Error bars represent the standard deviations from two independent experiments. NS, no differences at a significance level of 0.05.
Antiviral Res, 2016, 132:38-45.. Nimodipine purchased from Selleck.
Purity & Quality Control
Choose Selective Calcium Channel Inhibitors
|Description||Nimodipine (BAY E 9736) is a dihydropyridine calcium channel blocker and an autophagy inhibitor, used in the treatment of high blood pressure.|
Nimodipine decreases both the peak amplitude and the integrated area of the AHP in an age- and concentration-dependent manner. Nimodipine (100 nM) significantly reduces the AHP in aging CA1 neurons. Nimodipine increases excitability in an age- and concentration-dependent manner by decreasing spike frequency accommodation (increasing the number of action potentials during prolonged depolarizing current injection). Nimodipine decreases accommodation only at higher concentrations in young CA1 neurons.  Nimodipine decreases the plateau phase of the calcium AP at concentrations as low as 100 nM in aging neurons and 10 mM in young rat neurons. 
|In vivo||Nimodipine results in reversible, dose-related suppression of the compound action potential of the auditory nerve (CAP; N1-P1), a prolongation of N1 latency at suprathreshold levels, an elevated CAP threshold, a decrease in N1 latency at a constant amplitude measured at CAP threshold, a reduction in cochlear microphonics (CM), and a reduction of the negative summating potential (SP) to a point where it becomes positive.  Nimodipine (10 mg/kg, SC), an L-type dihydropyridine Ca2+ channel antagonist, appears to completely block the establishment of conditioning of cocaine's effects, but only partially blocks sensitization to cocaine.  Nimodipine (5-20 mg/kg, SC) inhibits in a dose-related manner self-administration both of cocaine and morphine contingent upon a nose-poke response. |
-  Moyer JR Jr, et al. J Neurophysiol,?992, 68(6), 2100-2109.
-  Moyer JR Jr, et al. Hippocampus,?994, 4(1), 11-17.
-  Bobbin RP, et al. Hear Res,?990, 46(3), 277-287.
|In vitro||DMSO||84 mg/mL (200.74 mM)|
|Ethanol||84 mg/mL (200.74 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Synonyms||BAY E 9736|
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04998370||Recruiting||--||Subarachnoid Hemorrhage Aneurysmal|Vasospasm|Delayed Cerebral Ischemia|Delayed Ischemic Neurological Deficit||University of Zurich||August 2021||--|
|NCT04649398||Recruiting||Drug: Nimodipine||Subarachnoid Hemorrhage Aneurysmal|Delayed Cerebral Ischemia|Vasospasm Cerebral||Medical University of Vienna|University of Vienna|Austrian Science Fund (FWF)||November 25 2020||--|
|NCT02991157||Completed||Drug: Nimodipine||Subarachnoid Hemorrhage Aneurysmal||National Institute of Mental Health and Neuro Sciences India||December 2016||--|
|NCT01835665||Completed||Drug: Nimodipine||Progranulin Mutation Carriers||University of California San Francisco|The Bluefield Project to Cure Frontotemporal Dementia||March 2013||Phase 1|
|NCT01551368||Terminated||Drug: Nimodipine|Drug: Placebo||Infertility||Mount Sinai Hospital Canada||December 2012||Phase 2|
|NCT01220622||Unknown status||Drug: Nimodipine|Drug: Placebo||Stroke|Mild Cognitive Impairment||Ministry of Science and Technology of the People´s Republic of China||October 2010||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.